Q-omics provides the consensus-scored MRPS26 profile across patient tissues and cancer cell-line models. MRPS26 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, MRPS26 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, MRPS26 protein abundance shows 25,421 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ESCA, BLCA, and LSCC as cancer lineages where MRPS26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS26 survival associations across molecular data types. MRPS26 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS26 RNA expression–survival associations across cancer types. High MRPS26 expression shows unfavorable associations in ESCA, UVM, LIHC, KICH, COAD and KIRC. The ESCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for MRPS26 RNA expression.
This table summarizes MRPS26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 8. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS26 shows higher tumor expression in BLCA, COAD, STAD, LUSC, LIHC and HNSC. The BLCA box plot shows higher MRPS26 RNA expression in tumor versus normal tissue (log2 FC = +1.082, t-test p < 0.001).
This table shows molecular features associated with MRPS26 in patient tissues and cancer cell lines. In patient samples, MRPS26 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
